NEW YORK (GenomeWeb News) – Pharmagogenomics firm DxS said today that it has signed an agreement with Amgen to market its K-RAS assay as a companion diagnostic for Amgen’s Vectibix (panitumumab) colorectal cancer therapy in the US.
 
Under the terms of the agreement, DxS’ TheraScreen K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix if approved by the US Food and Drug Administration, DxS said. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.